For millions of people worldwide, central vision depends on a tiny area of the retina called the macula. When that area deteriorates, Age-Related Macular Degeneration develops — progressively stripping away the ability to read, drive or recognize faces. AMD has long ranked among the leading causes of vision impairment in older adults. However, it now commands unprecedented attention from pharmaceutical companies, researchers and policymakers. The reason is straightforward: the world is aging fast, and AMD is aging with it.
What Is Age-Related Macular Degeneration
AMD is a progressive eye disease affecting primarily people over 50. It damages the central retina while typically leaving peripheral vision intact. Nevertheless, the functional impact is profound. Reading, driving and screen use all become significantly harder as the disease advances. AMD presents in two forms. Dry AMD develops gradually and accounts for roughly 80 to 90% of all cases. Wet AMD is less common but more aggressive — characterized by abnormal blood vessel growth beneath the retina that can cause rapid vision deterioration. Currently, more than 196 million people globally live with AMD, placing it among the most prevalent ophthalmic disorders in the world.
Market Size and Growth Projections
The global AMD market is projected to grow from US$ 12.21 billion in 2025 to US$ 23.25 billion by 2034, representing a compound annual growth rate of 7.42% from 2026 to 2034, according to Renub Research. That near-doubling of market size over less than a decade reflects both the rising patient population and the accelerating pace of therapeutic innovation. Furthermore, the market’s trajectory is supported by improving diagnostic rates, expanding treatment access in emerging economies and a growing pipeline of next-generation therapies. Consequently, AMD is emerging as one of the most dynamic and commercially significant segments within global ophthalmology.
Aging Demographics Driving Demand
A Global Population Growing Older
Demographics are the most powerful force behind AMD market growth. The global population is aging at an unprecedented pace. Japan, Italy, Germany, Portugal and Finland already have some of the world’s highest percentages of citizens aged 65 and older. As those populations continue to expand, healthcare systems face rising demand for AMD diagnosis and treatment. Moreover, the trend is no longer confined to developed economies. Emerging markets are also seeing rapid growth in elderly populations, creating new opportunities across the AMD value chain.
The Scale of What Is Coming
By 2030, global health organizations estimate that one in every six people worldwide will be aged 60 or older. By 2050, the number of people over 60 is expected to exceed two billion. These figures represent a long-term demographic foundation for sustained AMD market growth that extends well beyond the current forecast period. Additionally, as life expectancy continues to rise, AMD will increasingly affect populations who still have decades of active life ahead — making effective treatment a quality-of-life priority, not just a clinical one.
Innovation Transforming AMD Treatment
From Limited Options to a Rich Pipeline
Historically, AMD was viewed as a condition with few effective treatment options. That perception has fundamentally changed. The introduction of anti-VEGF therapies marked a major breakthrough — helping prevent abnormal blood vessel growth in wet AMD and slowing or partially reversing vision loss in some patients. Today, pharmaceutical companies invest heavily in next-generation therapies designed to improve outcomes while reducing treatment burden. Researchers focus on longer-lasting drug formulations, reduced injection frequency, personalized treatment approaches, gene therapy solutions, sustained-release delivery systems and geographic atrophy therapies. In 2025, the FDA approved expanded labeling for IZERVAY, broadening treatment possibilities for geographic atrophy — an advanced stage of dry AMD. This approval illustrates how rapidly the treatment landscape is evolving.
Early Diagnosis as a Competitive Advantage
Modern diagnostic technologies have significantly improved the ability to detect AMD before severe vision loss occurs. Advanced tools including Optical Coherence Tomography, retinal imaging systems and digital fundus photography now allow clinicians to identify subtle retinal changes far earlier than was previously possible. Additionally, public awareness campaigns increasingly encourage older adults to prioritize regular eye examinations. Earlier diagnosis benefits every stakeholder — patients gain timely access to treatment, physicians achieve better clinical outcomes and pharmaceutical companies access a broader eligible patient population. As diagnostic rates continue to improve globally, identified AMD patient numbers will grow — creating additional demand across the treatment market.
Dry AMD: The Largest and Most Underserved Segment
Dry AMD represents the largest segment of the market, accounting for approximately 80 to 90% of diagnosed cases worldwide. For years, treatment options for dry AMD were severely limited — creating substantial unmet medical need. However, researchers now actively pursue innovative therapies targeting disease progression and geographic atrophy. This growing research focus attracts investment and creates commercial opportunities that did not exist a decade ago. As diagnostic rates improve and the dry AMD patient population expands, demand for emerging therapies in this segment will intensify significantly. Dry AMD’s combination of high prevalence and historically limited treatment options makes it one of the most commercially important frontiers in ophthalmology today.
Key Products Shaping Market Competition
Three major products currently dominate the AMD treatment landscape. Eylea has established itself as one of the most widely used anti-VEGF therapies for wet AMD, valued for its effectiveness and relatively extended dosing intervals. Lucentis helped define modern AMD treatment standards and retains strong physician familiarity despite increasing competition from newer alternatives. Beovu, as a newer-generation anti-VEGF therapy, offers the potential advantage of longer treatment intervals — fewer injections that can improve patient convenience and adherence. Competition among these products drives ongoing innovation, ultimately expanding treatment choices for patients. Furthermore, the emergence of biosimilar alternatives for established anti-VEGF therapies is expected to influence pricing dynamics and market access patterns across regions.
Challenges Still Facing the AMD Market
Significant challenges persist alongside the market’s growth opportunity. Cost remains the most important obstacle. Many AMD therapies require repeated injections over extended periods, creating substantial financial burden for patients and healthcare systems. In lower-income regions with limited insurance coverage, those costs become prohibitive. Treatment expenses extend beyond medication — diagnostic procedures, specialist consultations, follow-up visits and monitoring programs all contribute to overall spending. Additionally, no definitive cure currently exists for AMD. Present therapies slow disease progression rather than eliminate it. Patients typically require lifelong monitoring and ongoing treatment to maintain visual function. The complexity of AMD biology also complicates drug development, as researchers continue searching for solutions capable of delivering more comprehensive and lasting benefits.
Regional Markets Leading Global Growth
The United States remains the world’s most important AMD market. Advanced healthcare infrastructure, strong reimbursement systems and extensive research activity all support market leadership there. The United Kingdom benefits from organized screening programs and strong public healthcare support driving patient access. India represents one of the fastest-growing opportunities globally — rising healthcare investment, expanding ophthalmology infrastructure and a growing elderly population all accelerate diagnosis and treatment adoption, though affordability remains a significant challenge. Saudi Arabia is strengthening its ophthalmology capabilities through healthcare modernization initiatives and greater investment in specialized medical services, creating conditions for continued market growth across the region.
